News und Analysen

• Best Agriculture Stocks to Buy in 2020

Bayer Aktiengesellschaft (ETR:BAYN) executives said the company’s Crop Science division remains on track with a five-year plan centered on cost savings

• Alnylam Stock Soars 65%: Find Out What’s Behind the Gains

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance

Insiders are making moves in three stocks that have seen huge shifts in value over the recent past. This includes insiders buying shares in names that have fallen more than 30% and sales hitting

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate

• DarioHealth is an AI-Powered Digital Therapeutics Play

DarioHealth (NASDAQ:DRIO) reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised

• MaxCyte: Building the Future of Cell and Gene Therapy Innovation

MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL

• 3 Small-Cap Leaders Poised for Significant Growth

AdaptHealth (NASDAQ:AHCO) told investors at a Bank of America event that first-quarter results reflected broad organic growth across its business

• 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel

• Best Agriculture Stocks to Buy in 2020

Bayer Aktiengesellschaft (ETR:BAYN) reported first-quarter 2026 results that management said were in line with expectations, as growth in Crop Science and

• 3 Reasons Analysts Love DexCom

Pediatrix Medical Group (NYSE:MD) reaffirmed its full-year 2026 adjusted EBITDA outlook after reporting what management described as a strong first quarter, supported

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma

• Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors

IQVIA (NYSE:IQV) reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing

• Bullish or Bearish? Vetting Animal Health Care Stocks

Elanco Animal Health (NYSE:ELAN) raised its 2026 outlook after reporting stronger-than-expected first-quarter results, citing broad-based

• 3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill

CVS Health (NYSE:CVS) raised its full-year 2026 adjusted earnings outlook after reporting stronger first-quarter results, with

Accel Entertainment (NYSE:ACEL) held its 2026 Annual Meeting of Stockholders, with shareholders voting to elect directors, approve executive compensation on an advisory basis and ratify the

• 3 Beaten Up Experiential Stocks to Cash in on a Good Time

Bowlero (NYSE:BOWL), referred to by executives on the call as Lucky Strike Entertainment, reported a modest increase in fiscal

• The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company

• Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs

Becton, Dickinson and Company (NYSE:BDX) reported fiscal second-quarter revenue and adjusted earnings ahead of its internal

• Zai Lab Stock Has Fallen to Value Levels

Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management